Communicable Disease Control

Communicable disease control is the sub-domain where the federal disruption pattern of 2025-26 has played out most visibly. The federal architecture (Public Health Service Act §§ 247b [PHEP](/paul/campaign/empower/glossary/#phep) / 247d [PHE](/paul/campaign/empower/glossary/#phe) declaration / 317 immunization; the [Vaccines for Children Program](/paul/campaign/empower/glossary/#vfc); [ACA](/paul/campaign/empower/glossary/#aca) § 2713 preventive services; CDC § 318 STD Prevention; the Ryan White HIV/AIDS Treatment Extension Act Parts A-F) is statutorily stable; the state framework (28 Pa. Code §§ 27.1-27.166 reportable diseases; Chapter 23 Subchapter C school immunizations) operates the substantive PA programs; the local framework ([PDPH](/paul/campaign/empower/glossary/#pdph) Communicable Disease Control division operating as a directly-funded CDC jurisdiction; [AACO](/paul/campaign/empower/glossary/#aaco) Philadelphia EMA Ryan White Part A planning council) delivers the front-end administration. Two federal-court resolutions in the verification window are the load-bearing events. The Braidwood SCOTUS resolution (Kennedy v. Braidwood Management, Inc., 606 U.S. 748, decided June 27, 2025) upheld the ACA § 2713 preventive services mandate nationwide. The Murphy preliminary injunction (D. Mass., Judge Brian E. Murphy, March 16, 2026, AAP v. Kennedy) restored the pre-January 2026 federal childhood vaccine schedule by staying the January 5, 2026 Decision Memo, blocking the reconstituted ACIP membership, and overturning the May 2025 Secretarial Directive halting COVID-19 vaccine recommendations for pregnant women and healthy children. The CDC Immunization Services Division and Partnership and Vaccine Equity Branch were terminated in August 2025 after being excluded from the Rhode Island injunction's narrowing.

Legal Architecture

Constitutional foundation

Communicable disease control rests on the same Spending Clause / 10th Amendment / 14th Amendment foundation as the broader public-health architecture (treated in the Public Health Infrastructure & Governance sub-domain). Kennedy v. Braidwood Management, Inc., 606 U.S. 748 (June 27, 2025), is the load-bearing constitutional case: the Supreme Court held that USPSTF members are inferior officers properly appointed under the Appointments Clause because the Secretary of HHS may remove them at will and review/block recommendations before they take effect. The 6-3 majority (Kavanaugh joined by Roberts, Sotomayor, Kagan, Barrett, Jackson; Thomas dissent joined by Alito, Gorsuch) reversed the Fifth Circuit and upheld the ACA § 2713 preventive services mandate. Cancer screenings, PrEP, tobacco cessation, and other USPSTF A/B services remain mandate-protected nationwide. The RFRA / PrEP religious-objection claim was remanded for proceedings limited to the Braidwood plaintiffs' employer-plan exemption.

Federal statutory layer

Public Health Service Act §§ 247b (PHEP), 247d (PHE declaration), 317 (immunization program). Treated at the framework level in the Public Health Infrastructure & Governance sub-domain. Statutory stability: HIGH; administrative vulnerability: HIGH at § 317 (appropriated levels and ACIP recommendation pathway).

Vaccines for Children Program (VFC), authorized through the National Childhood Vaccine Injury Act of 1986. Provides federal-purchased vaccines at no cost to children who are Medicaid-enrolled, uninsured, American Indian / Alaska Native, or underinsured (through Federally Qualified Health Centers). Statutory stability: HIGH; administrative vulnerability: MODERATE — depends on the ACIP recommendation pathway.

ACA § 2713, 42 U.S.C. § 300gg-13. Requires private health insurance plans, Medicaid managed care, and marketplace plans to cover USPSTF Grade A/B preventive services without cost-sharing — PrEP, USPSTF cancer screenings, tobacco cessation counseling, STI screenings, and others. Statutory stability: HIGH per Kennedy v. Braidwood.

CDC § 318 STD Prevention program. Federal grant funding to state and local STD prevention programs. Statutory stability: HIGH; administrative vulnerability: MODERATE — appropriated levels variable.

Ryan White HIV/AIDS Treatment Extension Act Parts A-F. Authorizes federal grants to Eligible Metropolitan Areas (Part A), states (Part B), early intervention services (Part C), special projects of national significance (Part D), AIDS Education and Training Centers (Part F), and the AIDS Drug Assistance Program. Statutory stability: HIGH; administrative vulnerability: MODERATE — appropriated levels variable.

Federal agency layer — five event-distinct disruptions

The CDC Advisory Committee on Immunization Practices is the institutional pivot of this architecture for vaccine policy. Five event-distinct treatments compose the disruption pattern.

Event 1 — Pre-injunction reconstitution and COVID-19 directive (May-December 2025). May 2025 Secretarial Directive halted CDC's recommendation of routine COVID-19 vaccines for pregnant women and healthy children. June 2025 Secretary Kennedy fired all 17 sitting ACIP voting members and reconstituted with 13 appointees largely drawn from vaccine-skeptic backgrounds. At its December 2025 meeting, the reconstituted ACIP voted to eliminate the universal hepatitis B birth-dose recommendation.

Event 2 — January 5, 2026 CDC Decision Memo (schedule reduction). Then-Acting CDC Director Jim O'Neill signed a Decision Memo demoting seven vaccines from universal recommendation to "shared clinical decision making" status: rotavirus, meningococcal, hepatitis A, hepatitis B, influenza, COVID-19, and respiratory syncytial virus. The Decision Memo cited a January 2026 Høeg/Kuldorff Assessment compared to "peer countries," particularly Denmark; the assessment was characterized in an AAP v. Kennedy amicus brief as employing "no generally accepted scientific methodology" with "misleading comparisons."

Event 3 — March 16, 2026 Murphy preliminary injunction. Judge Brian E. Murphy of the U.S. District Court for the District of Massachusetts (1st Circuit) — not the Sixth Circuit as some prior reporting suggested — granted a wide-ranging preliminary injunction in American Academy of Pediatrics et al. v. Kennedy et al. Plaintiffs include AAP, ACOG, AAFP, IDSA, ACP, SMFM, the Massachusetts Public Health Alliance, and an individual pregnant physician; suit was filed July 2025 originally challenging the May 2025 COVID-19 directive and amended four times. Judge Murphy found that the reconstituted ACIP failed FACA expertise requirements (only 6 of 15 members had meaningful vaccine expertise); the January 2026 Decision Memo was "arbitrary and capricious" because it "abandoned the agency's longstanding practice of getting recommendations from ACIP before changing the immunization schedules without sufficient explanation"; and the schedule reduction was both a "technical, procedural failure" and "an abandonment of the technical knowledge and expertise embodied by that committee." The injunction stays the Decision Memo, blocks the reconstituted ACIP membership, invalidates three reconstituted-ACIP votes, and overturns the May 2025 COVID-19 directive. HHS appealed to the First Circuit.

Event 4 — April 9, 2026 ACIP charter renewal. HHS published a renewed ACIP charter (Federal Register filing referenced as April 6 by some sources) broadening committee scope to include "vaccine safety research gaps," "cumulative effects" of childhood vaccines, aluminum adjuvants, "novel vaccine platforms such as mRNA," and reviewing "vaccine schedules used by other countries." The charter added non-voting liaison members from vaccine-skeptic organizations (Independent Medical Alliance; Physicians for Informed Consent; Association of American Physicians and Surgeons). HHS spokesperson Andrew Nixon characterized the renewal as "routine statutory requirements." 130+ medical, public-health, and patient advocacy organizations issued a statement of concern dated April 9. The charter renewal stands; the reconstituted ACIP membership remains blocked by the Murphy injunction; the body cannot meet. Previously approved vaccines (Moderna mRNA flu; Pfizer/Valneva Lyme; RSV vaccines for adults 18-49) await ACIP recommendation through an uncertain pathway.

Event 5 — Braidwood resolution (June 27, 2025). Kennedy v. Braidwood Management, Inc., 606 U.S. 748 (2025), reversed the Fifth Circuit and upheld the ACA § 2713 preventive services mandate. Important caveat: Braidwood did not directly address ACIP (vaccines) or HRSA Women's Preventive Services. The RFRA / PrEP religious-objection claim was remanded for proceedings limited to the Braidwood plaintiffs' employer-plan exemption.

Sixth event — HHS mRNA vaccine wind-down (August 5, 2025). HHS announced a "coordinated wind-down" of mRNA vaccine development under BARDA, terminating 22 BARDA contracts worth approximately $500 million and de-scoping mRNA-related work in additional contracts. Specific actions: contracts with Emory University and Tiba Biotech terminated; contracts with Luminary Labs, ModeX, and Seqirus de-scoped; pre-award solicitations from Pfizer, Sanofi Pasteur, CSL Sequirus, and Gritstone rejected/canceled; DoD JPEO collaborations restructured. Predecessor action: HHS terminated a $590 million Moderna H5N1 grant in May 2025. The mRNA wind-down affects future-vaccine pipeline rather than current immunization availability.

CDC ISD termination as consequence of Rhode Island narrowing. The CDC Immunization Services Division and Partnership and Vaccine Equity Branch — which had received April 1, 2025 RIF notices — were not protected by the State of Rhode Island v. Trump injunction's August 12, 2025 narrowed scope and were terminated. PVEB had supported state health department efforts to improve immunization rates in hesitant populations including those affected by measles outbreaks. The loss of federal capacity for state-level immunization equity support is material to PA-3's communicable disease infrastructure.

State statutory layer

28 Pa. Code §§ 27.1-27.166 (reportable diseases). The PA reportable disease framework. Statutory stability: HIGH; administrative vulnerability: MODERATE — implementation regulations are administratively set; the PA Code is current through 56 Pa.B. 778 (January 31, 2026).

28 Pa. Code Chapter 23, Subchapter C, §§ 23.81-87 (school immunization requirements). PA's school-entry immunization framework. Statutory stability: HIGH.

State agency layer

PA Department of Health. Continues to administer the framework. No PA DOH public divergent-position announcement post-Murphy ruling was located in the verification cycle. The Murphy preliminary injunction effectively restored the pre-January 2026 federal schedule, which aligns with PA's existing 28 Pa. Code Subchapter C rule; the question of state divergence is currently moot while the injunction holds.

Local statutory and local agency layer

PDPH Communicable Disease Control division. Operates within Philadelphia Code Title 6 authority (treated in the Public Health Infrastructure & Governance sub-domain). PDPH receives the directly-funded HIV Prevention Cooperative Agreement (direct CDC funding) and operates as one of CDC's directly-funded jurisdictions.

AACO Philadelphia EMA Ryan White Part A planning council. Administers Ryan White Part A allocations to the Philadelphia Eligible Metropolitan Area. FY26 specific allocations are partially unverified at the sub-domain level.

Cross-cutting structural features

Feature 1 — Five aggressive rollback events met one court check. The May 2025 COVID-19 directive, the June 2025 ACIP firing and reconstitution, the December 2025 hep B birth-dose vote, the January 5, 2026 Decision Memo, and the April 9, 2026 charter renewal were each separate disruption events. The Murphy preliminary injunction undid the first four; the April 9, 2026 charter renewal stands as a governance event but the body cannot meet. The pre-January 2026 federal childhood schedule is effectively restored.

Feature 2 — Braidwood as durable structural preservation. The Braidwood resolution preserved the ACA § 2713 preventive services mandate nationwide. PrEP coverage, USPSTF cancer screenings, tobacco cessation, and STI screening are durable post-Braidwood. The narrow caveat is the remanded RFRA religious-objection claim limited to the Braidwood plaintiffs' employer-plan exemption.

Feature 3 — Court-imposed checks preserve statutory protections but do not restore lost institutional capacity. The Rhode Island injunction protected most CDC offices and FDA CTP but its August 12, 2025 narrowing excluded the CDC Immunization Services Division and Partnership and Vaccine Equity Branch, which were terminated. The federal capacity for state-level immunization equity support is no longer present; PDPH absorbs the capacity loss.

Constituent profiles

These profiles illustrate the structural features above. The pathways are drawn from current law applied to documented PA-3 conditions; the people are composites with no claim to identifiable individuals.

Profile 1: North Philadelphia family with school-age child on restored federal schedule

Constituent type: a household with school-age children residing in a North/Northwest Philadelphia Core tract; the household uses the VFC vaccine pathway through a pediatric provider participating in VFC.

Pathway through the institutional system. The household pediatric provider faces the question of which vaccines are currently CDC-recommended at the routine well-child visit. Between January 5, 2026 and March 16, 2026, the federal recommendation status of seven vaccines (rotavirus, meningococcal, hep A, hep B, flu, COVID, RSV) was demoted by the CDC Decision Memo to "shared clinical decision making"; this affected provider counseling and insurance coverage signals. After Murphy's March 16, 2026 preliminary injunction, the pre-January 2026 federal schedule is restored. Approximately ten weeks of disruption.

Outcome. The household's pediatric vaccinations are recommended on the restored schedule. The First Circuit appeal could alter the pathway; PA continues to operate under 28 Pa. Code Chapter 23 Subchapter C without divergent state posture.

Profile 2: West Philadelphia PrEP user under Braidwood-preserved coverage

Constituent type: a PA-3 adult resident in West Philadelphia Core with HIV pre-exposure prophylaxis prescription via ACA-compliant insurance plan or Medicaid managed care.

Pathway through the institutional system. USPSTF Grade A recommendation for PrEP among at-risk individuals → ACA § 2713 mandate → no-cost-sharing coverage at participating pharmacy. Braidwood resolved June 27, 2025, 6-3, upholding the mandate nationwide. The RFRA exemption was remanded for plaintiff-specific application; the broader mandate stands.

Outcome. The user accesses PrEP without cost-sharing. The protection is durable post-Braidwood — the most consequential single positive event for PA-3 preventive-services access in the verification window.

Profile 3: PA-3 resident accessing screening through PDPH HIV Prevention Cooperative Agreement

Constituent type: a PA-3 adult resident with HIV-prevention-relevant screening need (TB; STI; HIV testing) accesses screening through PDPH-supported infrastructure.

Pathway through the institutional system. Clinic visit at a PDPH-affiliated or AACO-supported site. PDPH HIV Prevention Cooperative Agreement provides direct CDC funding for prevention infrastructure; AACO Ryan White Part A provides treatment services for people with HIV (PWH). FY26 allocation is partially unverified at the sub-domain level.

Outcome. Screening proceeds within current PDPH capacity. FY26 funding fluctuation is the operative concern at the policy level.

Conversational note

Communicable disease control is the sub-domain where the federal disruption pattern of 2025-26 has played out most visibly. Five distinct events between May 2025 and April 2026 — the Secretarial Directive halting COVID-19 recommendations for pregnant women and healthy children; the firing and reconstitution of ACIP; the December 2025 ACIP vote eliminating the universal hepatitis B birth-dose recommendation; the January 5, 2026 Decision Memo demoting seven vaccines from universal recommendation to "shared clinical decision making" status; and the April 9, 2026 ACIP charter renewal broadening the committee's scope to include vaccine-skeptic territory — represented the most aggressive federal rollback of the routine childhood immunization framework in the program's modern history. For PA-3 families with school-age children, this period was the most destabilized stretch in the recent operational history of the federal recommendation pathway.

The Murphy preliminary injunction of March 16, 2026 — granted in the District of Massachusetts by Judge Brian E. Murphy — effectively restored the pre-January 2026 federal childhood schedule. The injunction stayed the Decision Memo, blocked the reconstituted ACIP membership, invalidated three reconstituted-ACIP votes, and overturned the May 2025 Secretarial Directive. In operational terms, what the injunction means for PA-3 pediatric care is that the routine childhood schedule that was operative through 2024 — including the universal hepatitis B birth dose, the routine COVID-19 recommendations for pregnant women and healthy children, and the universal recommendations for all seven vaccines that had been demoted — is the operative federal schedule again, pending the First Circuit appeal. The broader ACIP charter renewal stands as a governance event but the body cannot meet under current conditions. The Murphy injunction is the most consequential single legal event in the federal communicable-disease-control architecture during the verification window.

For PA-3 PrEP users, cancer screening patients, and others depending on USPSTF A/B services covered without cost-sharing under ACA § 2713, the Kennedy v. Braidwood Management, Inc. resolution of June 27, 2025 was the equivalent positive event. The Supreme Court ruled 6-3 that USPSTF members are properly appointed inferior officers because the Secretary may remove them at will and review their recommendations. The mandate was upheld nationwide. Pennsylvania PrEP users, screening-eligible patients, and others continue to receive these services without cost-sharing through ACA-compliant private insurance plans, Medicaid managed care plans, and marketplace plans. The CDC ISD termination — a consequence of the Rhode Island injunction's August 12, 2025 narrowing — is the structural counterweight: the federal capacity for state-level immunization equity support, which historically supported PDPH outreach in tracts with documented hesitancy, is no longer present. The federal architecture for communicable disease control in 2026 is, in summary, mostly restored to the pre-disruption posture by court order, but operating with reduced federal-state partnership capacity.

Geography & representation

Data provenance. Kennedy v. Braidwood Management, Inc., 606 U.S. 748 (June 27, 2025) is documented in the SCOTUS opinion text. The Murphy preliminary injunction in AAP v. Kennedy (D. Mass., March 16, 2026; HHS appeal to 1st Cir.) is documented in court filings. The five ACIP-related disruption events are documented in HHS press releases, CDC Decision Memo text, and Federal Register filings. The HHS mRNA wind-down (August 5, 2025; 22 BARDA contracts terminated; approximately $500 million) is documented in the HHS press release. The Rhode Island injunction's August 12, 2025 narrowing excluding CDC ISD is documented in court filings. AACO Philadelphia EMA Ryan White Part A FY26 allocation, PDPH HIV Prevention Cooperative Agreement FY26 levels, and CDC § 318 STD Prevention FY26 levels are flagged for institutional-source retrieval. PA continues operating under existing 28 Pa. Code Chapter 23 Subchapter C without divergent state posture per the verification cycle.

PA-3 statistical profile. Philadelphia is one of CDC's directly-funded jurisdictions for HIV prevention; PDPH operates the AACO Philadelphia EMA infrastructure. The PA-3 PrEP-using population, the population with USPSTF preventive-services-eligible screening needs, and the school-age population on the routine childhood immunization schedule are each served through the federal-state-local architecture under the post-Murphy and post-Braidwood operational posture.

Geographic variation.

North/Northwest Philadelphia Core. Heaviest concentration of PA-3 residents historically engaged by CDC ISD / PVEB-supported immunization-equity outreach that has been terminated. Tract-level immunization-rate disaggregation was not located in the verification cycle.
West Philadelphia Core. Substantial PWH population; AACO Ryan White Part A service delivery operates citywide rather than tract-disaggregated.
Northwest Philadelphia. PDPH outreach operates at city level; tract-level data not in the verification cycle.
South/Southwest Philadelphia. Same city-level pattern.

District-by-tract disaggregation of immunization rates and Ryan White service utilization is not available at the sub-domain level. Sub-area variation is presented as structural inference from PDPH district reporting and the geographic concentration of disadvantaged populations established at the project frame.

Pathway tracing.

ACIP recommendation → VFC eligibility → school-entry compliance. Historic operating pathway: ACIP recommends → CDC adopts → VFC and private insurance coverage follow → state references in 28 Pa. Code Chapter 23 Subchapter C → school-entry compliance check at 28 Pa. Code § 23.83 (note: registry typo "§ 28.83" in a prior cycle corrected here to § 23.83). Pathway breakdown points: the Murphy injunction blocks the reconstituted ACIP; pre-January 2026 schedule restored as the operative federal schedule; First Circuit appeal pending; PA does not currently diverge.
Braidwood-protected preventive services through ACA-compliant insurance. ACA § 2713 → USPSTF recommendation → no-cost-sharing in ACA-compliant plans (private insurance + Medicaid managed care + marketplace) → PA-3 patient access. Pathway breakdown points: none currently — Braidwood resolved June 27, 2025; mandate upheld; preventive services protections preserved.
Ryan White Part A → AACO Philadelphia EMA → service delivery to people with HIV. AACO Philadelphia EMA receives Part A allocation; planning council allocates services to PWH in the EMA. Pathway breakdown points: FY26 PA and Philadelphia direct allocations partially unverified; AACO administrative capacity stable.
PDPH HIV Prevention Cooperative Agreement. PDPH receives direct CDC funding; FY26 levels partially unverified.
HHS mRNA wind-down → reduced future-vaccine pipeline. August 5, 2025 wind-down terminated 22 BARDA contracts worth approximately $500 million; this affects future pandemic-preparedness pipeline rather than current immunization availability.

Representation question. The PHSA + ACA framework promises PA-3 residents science-informed routine childhood immunization recommendations through ACIP; federal-program access through VFC for low-income and uninsured children; preventive services without cost-sharing under ACA § 2713 (PrEP, USPSTF cancer screenings, tobacco cessation, STI screenings); HIV prevention infrastructure through PDPH directly-funded jurisdiction status; Ryan White treatment access for PWH through AACO Philadelphia EMA; and state and local administration (PA DOH; PDPH) of communicable disease surveillance and response under 28 Pa. Code §§ 27 + Chapter 23 Subchapter C. As of mid-2026, PA-3 constituents face a federal recommendation pathway operating under court order (Murphy injunction blocking the reconstituted ACIP and restoring the pre-January 2026 schedule); a preventive-services mandate that is durable post-Braidwood; a state framework that aligns with federal default (no PA divergence announced); CDC ISD termination eliminating federal-state immunization-equity partnership capacity; and FY26 PHEP/ELC, PDPH HIV Prevention, and AACO Ryan White Part A allocations partially unverified. The MAHA-era institutional restructuring delivered five aggressive rollback events between May 2025 and April 2026; the Murphy injunction and the Braidwood resolution constrained the most aggressive elements; the institutional capacity destruction (CDC ISD termination) is not undone by the litigation pathway. PA-3 residents continue to receive most of the communicable-disease-control protections that the statutory architecture promises, with two qualifications: the institutional capacity behind those protections is operationally degraded (CDC ISD; CBER leadership churn; FDA workforce reduction), and the federal recommendation pathway is functioning under court order rather than under independent ACIP operation. The litigation pathway has been the operative check on the rollback; without it the protection picture would be substantially worse.

Gap analysis

Gap 1 — PHEP/ELC operational reliance for PDPH communicable disease surveillance (G2-SD2-01). PDPH communicable-disease surveillance capacity depends substantially on CDC PHEP and ELC cooperative agreements. FY26 specific PA and Philadelphia direct allocations are partially unverified at the sub-domain level.

Gap 2 — PA reportable-disease infrastructure (G2-SD2-02). The PA reportable-disease framework operates under 28 Pa. Code § 27 et seq. with PDPH executing local surveillance through Philadelphia Code Title 6 authority. The statutory framework is verified by citation; operational sufficiency depends on PDPH staffing and PHEP/ELC funding levels.

Gap 3 — ACIP charter rewrite implementation impact on VFC and federal-program coverage (G2-SD2-03). The April 9, 2026 charter renewal stands as a scope-broadening event; substantive impact is mediated by the Murphy injunction blocking the reconstituted membership. Previously approved vaccines (Moderna mRNA flu, Pfizer/Valneva Lyme, RSV vaccines for adults 18-49) face an uncertain recommendation pathway with insurance and VFC implications.

Gap 4 — Childhood schedule litigation under court check (G2-SD2-04). American Academy of Pediatrics et al. v. Kennedy et al. is in the District of Massachusetts (Judge Brian E. Murphy; 1st Circuit), not the Sixth Circuit as some prior reporting suggested. Preliminary injunction issued March 16, 2026; HHS appealed to the First Circuit; underlying case continues. The court denied the government's motion to dismiss earlier in the case.

Gap 5 — PA school-entry schedule decision moot under restored federal default (G2-SD2-05). PA continues operating under existing 28 Pa. Code Chapter 23 Subchapter C; no PA DOH public divergent-position announcement was located post-Murphy. The question of state divergence is moot while the injunction holds and the pre-January 2026 federal schedule is restored. The structural question is whether PA would diverge if the First Circuit reversed the Murphy injunction — a question the verification cycle did not resolve.

Gap 6 — Braidwood-dependent treatment access preserved (G2-SD2-06). The ACA § 2713 mandate is upheld nationwide; preventive STI screening cost-sharing protections preserved; PrEP coverage requirement preserved. ACIP-related concerns are separate litigation tracks. The narrow caveat is the remanded RFRA religious-objection claim limited to the Braidwood plaintiffs' employer-plan exemption.